drugset / Trial / NCT00928798

Topical Rapamycin for Fibrofolliculomas

NCT00928798

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones. Secondary we evaluate rapamycin safety, formula acceptance and patient satisfaction.

Timeline

Start
2010-01
Primary completion
2011-02
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 1 mg/ml Topical